Table 3 Mean estimates of each QL indicator from the (a) IBCSG Core Form and (b) trial-specific module by treatment group at months 0, 3, 6, 9, 12, and 18 months from randomisation^a

From: Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer

	Months from randomisation
	0			3			6			9			12			18
QL	SD-CT	DI-EC	P -value	SD-CT	DI-EC	P -value	SD-CT	DI-EC	P -value	SD-CT	DI-EC	P -value	SD-CT	DI-EC	P -value	SD-CT	DI-EC	P -value
(a)
Physical well-being	84±2	87±2	0.24	73±3	52±4	<0.01	75±3	84±3	0.01	88±2	87±2	0.76	89±2	89±2	0.90	88±2	90±2	0.30
Mood	74±3	74±3	0.95	74±3	64±4	0.01	76±3	84±3	0.02	85±2	83±2	0.51	86±2	87±2	0.71	88±2	89±2	0.52
Tiredness	76±3	78±3	0.42	56±4	46±5	0.05	59±4	73±4	<0.01	69±3	75±3	0.12	76±3	76±3	0.94	74±3	81±3	0.03
Appetite	89±2	90±2	0.60	81±3	58±4	<0.01	85±2	88±2	0.27	92±2	92±2	0.84	94±2	93±2	0.97	94±1	94±2	0.94
Hot flushes	93±2	94±2	0.65	84±3	90±3	0.05	76±4	79±4	0.60	68±4	71±4	0.44	68±4	77±4	0.05	63±5	70±5	0.16
Nausea/vomiting	96±1	98±1	0.23	74±3	74±3	0.83	84±2	96±1	<0.01	98±1	97±1	0.46	97±1	98±1	0.56	98±1	98±1	0.71
Coping effort	60±4	61±4	0.94	60±4	51±4	0.06	62±4	76±3	<0.01	73±3	78±3	0.12	77±3	78±3	0.83	78±3	83±3	0.09
Feel supported	97±1	97±1	0.87	93±1	96±1	0.04	93±1	96±1	0.07	94±1	94±1	0.91	93±1	94±1	0.40	93±1	95±1	0.18
Arm restriction	71±3	71±3	0.84	83±2	81±3	0.49	85±2	82±3	0.44	83±2	81±3	0.49	80±3	82±3	0.51	84±2	83±3	0.67
Subjective health	75±2	73±3	0.65	65±3	61±4	0.30	67±3	79±3	<0.01	75±3	83±2	0.01	79±2	84±2	0.06	80±2	86±2	0.01
(b)
Hair loss	94±2	96±1	0.24	36±5	34±6	0.79	83±3	85±3	0.63	94±2	93±2	0.63
Numbness	92±2	93±1	0.63	88±2	90±2	0.43	89±2	88±2	0.81	91±2	87±2	0.16
Thoughts	60±3	58±4	0.66	63±3	53±4	0.05	70±3	84±3	<0.01	89±2	89±2	0.83
Sexual interest	81±3	77±3	0.38	64±4	62±4	0.76	63±4	80±3	<0.01	79±3	83±3	0.28
Sore mouth	98±1	98±1	0.70	85±2	65±4	<0.01	90±2	96±1	0.01	97±1	98±1	0.58
Pain	90±2	91±2	0.74	88±2	84±2	0.11	88±2	91±2	0.34	90±2	92±2	0.44
Treatment burden	78±2	76±3	0.59	64±3	50±4	<0.01	68±3	81±3	<0.01	86±2	82±3	0.24
Daily activity	74±2	74±3	0.99	68±3	52±4	<0.01	73±3	79±3	0.06	82±2	84±2	0.49

Abbreviations: QL=quality of life; DI-EC=dose-intensive epirubicin cyclophosphamide; SD-CT=standard dose chemotherapy (ACx4-CMFx3). Higher scores indicate a better condition for all indicators.
Estimates were obtained from a linear mixed-effects model adjusted for patients’ age, culture, and baseline score.

Back to article page

Table 3 Mean estimates of each QL indicator from the (a) IBCSG Core Form and (b) trial-specific module by treatment group at months 0, 3, 6, 9, 12, and 18 months from randomisation^a

Search

Quick links